Articulation of Quality By Design Elements for Product Development and its Unique Applications
Quality by Design (QbD) is a methodical approach to pharmaceutical product development that begins with predefined objectives and emphasizes product and process comprehension and process control based on sound science and quality risk management. Pharmaceutical development should lead to the design a quality product and its manufacturing process to meet the QTPP and CQA parameters. To arrive at the robust product development QbD articulation is important which is missing in most of the reviews. This review articulates the QbD elements in the product development. QbD process stars with identification of QTPP and source CQA from QTPP. CMAs and CPPs are derived with risk assessment from the product ingredients and process. Their impact on the CQAs can be studies with DoE tools. The information and knowledge gained from pharmaceutical development studies and manufacturing experience provide scientific understanding to support the design space and control strategy. Product process follows life cycle management approach with continuous improvement. PAT tools are utilized for the online monitoring of the processes. This review paper is dedicated to provide QbD element articulation in product development and its unique applications in the various areas of the product development such as Biotechnology, Nanotechnology products, Nasal products, Inhalation, Injectable products, Targeted drug delivery, complex Solid oral, Transdermal and topical products, Bioavailability and dissolution enhancement, Analytical processes and API manufacturing etc. Current trends in the technical application of the PAT tools are discussed.
Keywords: Quality by Design (QbD), Quality Target Product Profile (QTPP), Critical Quality Attributes (CQA) and Design of Experiment (DoE): Product development application of QbD
2. Yu LX. Pharmaceutical Quality by Design: Product and Process Development, Understanding and Control. Pharm Res 2008; 25:781-791.
3. Lawrence XY, Gregory A, Khan MA, Hoag SW, Polli J, Raju GK et al. Understanding Pharmaceutical Quality by Design. AAPS J 2014; 16(4):771-783.
4. Vemuri PN, Gupta V. A. Review on quality by design approach (QBD) for Pharmaceuticals. Int J Drug Dev Res 2015; 7(1):52-60.
5. Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: Regulatory need. Arab J Chem 2017; 10:S3412-S3425.
6. Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J. Pharmaceutical product development: A quality by design approach. Int J Pharma Investig 2016; 6:29-138.
7. Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 2009; 27(9):546-553.
8. Eziokwu NV. Quality by design (QbD): Manufacturing and product quality of generics drugs perspective. J Global Trends Pharm Sci 2013; 4(4):1257-62.
9. Fukuda IM, Pinto CF, Moreira CD, Saviano AM, Lourenço FR. Design of Experiments (DoE) applied to pharmaceutical and analytical Quality by Design (QbD). Braz J Pharm Sci 2018; 54.
10. Raw AS, Lionberger R, Lawrence XY. Pharmaceutical equivalence by design for generic drugs: modified-release products. Pharm Res 2011; 28(7):1445-53.
11. Chavan SD, Pimpodkar NV, Kadam AS, Gaikwad PS. Quality by Design. Journal of Pharmaceutical Quality Assurance 2015; 1(2):18-24.
12. Anuj G, Fuloria DN. Short review on Quality by design: A new Era of Pharmaceutical drug development. Int J Pharm Pharm Sci 2012; 4(3):19-26.
13. Jain S. Quality by design (QBD): A comprehensive understanding of implementation and challenges in pharmaceuticals development. Int J Pharm Pharm Sci 2014; 6:29-35.
14. Zalai D, Dietzsch C, Herwig C. Risk-based process development of biosimilars as part of the quality by design paradigm. PDA J Pharm Sci Tech 2013 Nov 1; 67(6):569-80.
15. Lambert WJ. Considerations in developing a target product profile for parenteral pharmaceutical products. AAPS Pharm Sci Tech 2010 Sep 1; 11(3):1476-81.
16. Kalyan A, Parle A. Quality by Design: Changing outlook of Pharmaceutical development Search Results. Int J Pharm Sci Res 2019; 10(9):4100-4108.
17. Mesut B, Ȍzsoy Y, Aksu B. The place of drug product critical quality parameters in quality by design (QbD). Turk J Pharm Sci 2015; 12(1):75-92.
18. Mohammed AQ, Sunkari PK, Srinivas P, Roy AK. Quality by design in action 1: controlling critical quality attributes of an active pharmaceutical ingredient. Org Process Res Dev 2015; 19(11):1634-44.
19. Zhang L, Mao S. Application of quality by design in the current drug development. Asian J Pharm Sci 2017;12:1–8
20. Chordiya MA, Gangurde HH, Sancheti VN. Quality by design: A Roadmap for quality pharmaceutical products. J Rep Pharm Sci 2019; 8:289-94.
21. Lionberger RA, Lee SL, Lee LM, Raw A, Lawrence XY. Quality by Design: Concepts for ANDAs. AAPS J 2008; 10(2):268-276.
22. Nadpara NP, Thumar RV, Kalola VN, Patel PB. Quality by Design (QbD): A Complete Review. Int J Pharm Sci Rev Res 2012; 17(2):20-28.
23. Nagar M, Panwar KS, Chopra VS, Bala I, Trivedi P. Quality by design: a systematic approach to pharmaceutical development. Der Pharmacia Lettre 2010;2(2):111-30.
24. Rogers A, Ierapetritou M. Challenges and opportunities in modeling pharmaceutical manufacturing processes. Comput Chem Eng 2015; 81:32-9.
25. Patil AS, Pethe AM. Quality by Design (QbD): A new concept for development of quality pharmaceuticals. International Journal of Pharmaceutical Quality Assurance 2013; 4(2):13-19.
26. Bendale HP, Bakliwal AA, Talele SG, Deshmukh SA, Chaudhari GN. Quality by Design: A Modern approach in Pharmaceutical development of Formulation. World J Pharm Res 2015; 4(3):402-422.
27. Sumit K, Shikha T, Deepika T, Ashish B. A quantitative approach for pharmaceutical quality by design patterns. Inveti Rapid: Pharm Anal Qual Assur 2012; (4):1-8.
28. Garcia T, Cook G, Nosal R. PQLI key topics-criticality, design space, and control strategy. J Pharm Innov 2008; 3(2):60-8.
29. Michaels JN, Bonsignore H, Hudson-Curtis BL, Laurenz S, Lin HR, Mathai T, Pande G, Sheth A, Sprockel O. Attribute-based design space: materials-science-based quality-by-design for operational flexibility and process portability. J Pharm Innov 2011; 6(4):193-201.
30. Jadhav JB, Girawale NN, Chaudhari RA. Quality by Design (QBD) Approach used in Development of Pharmaceuticals. Int J Pure App Biosci 2014; 2(5):214-223.
31. Tambe K, Bonde S. A review on: Applications of pharmaceutical quality by design in product development. World J Pharm Sci 2017; 5(1):58-70.
32. Elliott P, Billingham S, Bi J, Zhang H. Quality by design for biopharmaceuticals: a historical review and guide for implementation. Pharm Bioprocess 2013; 1(1):105-22.
33. Grangeiaab HB, Silvaa C, Simõesab SP, Marco S. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. Eur J Pharm Biopharm 2020; 147:9-37.
34. Udugade SB, Udugade BV, Mandhare TA. Pharmaceutical Quality by Design: A Hopeful Ray for Quality Product. Int J Med Pharm Res 2016; 4(5):297-300.
35. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), ICH Harmonised Tripartite Guideline, Pharmaceutical Development, Q8(R2), 2009.
36. Purohit PJ, Shah KV. Quality by Design (QbD): New parameter for quality improvement & pharmaceutical drug development. Pharm Sci Monitor 2013; 3(3).
37. Hulbert MH, Feely LC, Inman EL, Johnson AD, Kearney AS, Michaels J, Mitchell M, Zour E. Risk management in the pharmaceutical product development process. J Pharma Innov 2008; 3(4):227-48.
38. Pallagi E, Ismail R, Paal TL, Csóka I. Initial risk assessment as part of the quality by design in peptide drug containing formulation development. Eur J Pharm Sci 2018; 122:160-9.
39. Politis N, Colombo P, Colombo G, M. Rekkas D. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm 2017; 43(6):889-901.
40. Patel H, Parmar S, Patel B. A Comprehensive Review on Quality by Design (QbD) in Pharmaceuticals. Int J Pharm Sci Rev Res 2013; 21(1):223-236.
41. Yacoub F, Lautens J, Lucisano L, Banh W. Application of quality by design principles to legacy drug products. J Pharm Innov 2011; 6(2):61.
42. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers (R4), 2010.
43. Ferreira AP, Tobyn M. Multivariate analysis in the pharmaceutical industry: enabling process understanding and improvement in the PAT and QbD era. Pharm Dev Tech 2015; 20(5):513-27.
44. Murphy T, O'Mahony N, Panduru K, Riordan D, Walsh J. Pharmaceutical manufacturing and the quality by design (QBD), process analytical technology (PAT) approach. 2016 27th Irish Signals and Systems Conference. IEEE. 1-7.
45. U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry, PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance 2004.
46. McKenzie P, Kiang S, Tom J, Rubin AE, Futran M. Can pharmaceutical process development become high tech?. AIChE Journal 2006; 52(12):3990-4.
47. Lee SL, O’Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, Moore CM, Lawrence XY, Woodcock J. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov 2015; 10(3):191-9.
48. Tabasi SH, Fahmy R, Bensley D, O'Brien C, Hoag SW. Quality by design, part I: Application of NIR spectroscopy to monitor tablet manufacturing process. J Pharm Sci 2008; 97(9):4040-51.
49. Tabasi SH, Fahmy R, Bensley D, O'Brien C, Hoag SW. Quality by design, part II: application of NIR spectroscopy to monitor the coating process for a pharmaceutical sustained release product. J Pharm Sci 2008; 97(9):4052-66.
50. Tabasi SH, Fahmy R, Bensley D, O'Brien C, Hoag SW. Quality by design, part III: study of curing process of sustained release coated products using NIR spectroscopy. J Pharm Sci 2008; 97(9):4067-86.
51. Corredor CC, Lozano R, Bu X, McCann R, Dougherty J, Stevens T, Both D, Shah P. Analytical method quality by design for an on-line near-infrared method to monitor blend potency and uniformity. J Pharm Innov 2015; 10(1):47-55.
52. Somma R. Development knowledge can increase manufacturing capability and facilitate quality by design. J Pharm Innov 2007; 2(3-4):87-92.
53. Schoenherr C, Haefele T, Paulus K, Francese G. Confocal Raman microscopy to probe content uniformity of a lipid based powder for inhalation: a quality by design approach. Eur J Pharm Sci 2009; 38(1):47-54.
54. Portillo PM, Ierapetritou M, Tomassone S, Mc Dade C, Clancy D, Avontuur PP, Muzzio FJ. Quality by design methodology for development and scale-up of batch mixing processes. J Pharm Innov 2008; 3(4):258-70.
55. Lee MJ, Seo DY, Lee HE, Wang IC, Kim WS, Jeong MY, Choi GJ. In line NIR quantification of film thickness on pharmaceutical pellets during a fluid bed coating process. International journal of pharmaceutics 2011; 403(1-2):66-72.
56. Hertrampf A, Müller H, Menezes JC, Herdling T. A PAT-based qualification of pharmaceutical excipients produced by batch or continuous processing. J Pharmaceut Biomed 2015; 114:208-15.
57. Xu X, Costa AP, Khan MA, Burgess DJ. Application of quality by design to formulation and processing of protein liposomes. Int J Pharm 2012; 434(1-2):349-59.
58. Nagashima H, Watari A, Shinoda Y, Okamoto H, Takuma S. Application of a quality by design approach to the cell culture process of monoclonal antibody production, resulting in the establishment of a design space. J Pharma Sci 2013; 102(12):4274-83.
59. Manteghi R, Pallagi E, Olajos G, Csóka I. Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach. Eur J Pharm Sci 2019. Doi: https://doi.org/10.1016/j.ejps.2019.105197
60. Rathore AS. Quality by design (QbD)-based process development for purification of a biotherapeutic. Trends in biotechnology. 2016; 34(5):358-70.
61. Marto J, Gouveia LF, Gonçalves LM, Gaspar DP, Pinto P, Carvalho FA, Oliveira E, Ribeiro HM, Almeida AJ. A quality by design (QbD) approach on starch-based nanocapsules: a promising platform for topical drug delivery. Colloid Surf B. 2016; 143:177-85.
62. Nicole S. Mendonsa, Adwait Pradhan, Purnendu Sharma, Rosa M.B. Prado, S. Narasimha Murthy, Santanu Kundu et al. A quality by design approach to develop topical creams via hot-melt extrusion technology. Eur J Pharm Sci 2019. Doi: https://doi.org/10.1016/j.ejps.2019.06.002
63. Qian Kang, Jia Liu, Xin-Yan Liu, Nuo-Lan Mo, Yong-Jie Wang, Ying Zhao et al. Application of quality by design approach to formulate and optimize Tripterine loaded in nanostructured lipid carriers for transdermal delivery. J Drug Deliv Sci Tec 2019; 52:1032-1041.
64. Raquel Fernández-García, Aikaterini Lalatsa, Larry Statts, Francisco Bolás-Fernández, M. Paloma Ballesteros, Dolores R. Serrano. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. Int J Pharm 2020. Doi: https://doi.org/10.1016/j.ijpharm.2019.118817
65. Jain S, Patel N, Madan P, Lin S. Quality by design approach for formulation, evaluation and statistical optimization of Diclofenac-loaded Ethosomes via transdermal route. Pharm Dev Tech. 2015; 20(4):473-89.
66. Park SY, Kang Z, Thapa P, Jin YS, Park JW, Lim HJ et al. Development of Sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach. Int J Pharm 2019; 566:229-238.
67. Yerlikaya F, Ozgen A, Vural I, Guven O, Karaagaoglu E, Khan MA, Capan Y. Development and evaluation of Paclitaxel nanoparticles using a quality-by-design approach. J Pharm Sci 2013; 102(10):3748-61.
68. Gurumukhi VC, Bari SB. Fabrication of Efavirenz loaded nano-formulation using quality by design (QbD) based approach: Exploring characterizations and in vivo safety. J Drug Deliv Sci Tec 2020. Doi: https://doi.org/10.1016/j.jddst.2020.101545
69. Mahtab A, Md. Rizwanullah, Pandey S, Leekha A, Rabbani SA, Verma A et al. Quality by design driven development and optimization of Teriflunomide loaded Nanoliposomes for treatment of rheumatoid arthritis: An in vitro and in vivo assessments. J Drug Deliv Sci Tec 2019; 51:383-396.
70. Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of Nanosuspension preparation. Int J Pharm Volume 2009;377(1–2):185-198.
71. Negi P, Singh B, Sharma G, Beg S, Katare OP. Biocompatible Lidocaine and Prilocaine loaded-nanoemulsion system for enhanced percutaneous absorption: QbD-based optimisation, dermatokinetics and in vivo evaluation. J Microencapsul 2015;32(5):419-31.
72. Zhang L, Zhang X, Li J, Broichsitter MB, Muenster U, Wang X et al. Optimization of Budesonide-loaded large-porous microparticles for inhalation using quality by design approach. J Drug Deliv Sci Tec 2019. Doi: https://doi.org/10.1016/j.jddst.2019.101140.
73. Buttini F, Rozou S, Rossi A, Zoumpliou V, Rekkas DM. The application of quality by design framework in the pharmaceutical development of Dry powder inhalers. Eur J Pharm Sci 2018; 113:64-76.
74. Bartos C, Pallagi E, Szabó-Révész P, Ambrus R, Katona G, Kiss T, Rahimi M, Csóka I. Formulation of Levodopa containing dry powder for nasal delivery applying the quality-by-design approach. Eur J Pharm Sci 2018; 123:475-483.
75. Deng Y, Zhong G, Wang Y, Wang N, Yu Q, Yu X. Quality by design approach for the preparation of Fat-soluble vitamins lipid injectable emulsion. Int J Pharm 2019. Doi: https://doi.org/10.1016/j.ijpharm.2019.118717
76. Porfire A, Muntean DM, Rus L, Sylvester B, Tomuţă I. A quality by design approach for the development of lyophilized liposomes with Simvastatin. Saudi Pharm J 2017; 25(7):981-992.
77. Zidan AS, Sammour OA, Hammad MA, Megrab NA, Habib MJ, Khan MA. Quality by design: understanding the product variability of a Self-nanoemulsified drug delivery system of cyclosporine A. J Pharm Sci 2007; 96(9):2409-23.
78. Hales D, Vlase L, Porav SA, Bodoki A, Barbu-Tudoran L, Achim M, Tomuță I. A quality by design (QbD) study on Enoxaparin sodium loaded polymeric microspheres for colon-specific delivery. Eur J pharm Sci 2017; 100:249-61.
79. Lange R, Ter Heine R, Van Der Gronde T, Selles S, De Klerk J, Bloemendal H, Hendrikse H. Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical Rhenium-188-HEDP. Eur J Pharm Sci 2016; 90:96-101.
80. Javed MN, Kohli K, Amin S. Risk assessment integrated QbD approach for development of optimized bicontinuous mucoadhesive limicubes for oral delivery of Rosuvastatin. AAPS Pharm Sci Tech 2018; 19(3):1377-91.
81. Lee AR, Kwon SY, Choi DH, Park ES. Quality by Design (QbD) approach to optimize the formulation of a bilayer combination tablet (Telmiduo®) manufactured via high shear wet granulation. Int J Pharm 2017; 534(1–2):144-158.
82. Saurí J, Millán D, Suñé-Negre JM, Colom H, Ticó JR, Miñarro M, Pérez-Lozano P, García-Montoya E. Quality by Design approach to understand the physicochemical phenomena involved in controlled release of Captopril SR matrix tablets. Int J Pharm 2014; 477(1–2):431-441.
83. Wang J, Kan S, Chen T, Liu J. Application of quality by design (QbD) to formulation and processing of Naproxen pellets by extrusion–spheronization. Pharm Dev Tech 2015; 20(2):246-56.
84. Lourenço V, Lochmann D, Reich G, Menezes JC, Herdling T, Schewitz J. A quality by design study applied to an industrial pharmaceutical fluid bed granulation. Eur J Pharm Biopharm 2012; 81(2):438-447.
85. Baldinger A, Clerdent L, Rantanen J, Yang M, Grohganz H. Quality by design approach in the optimization of the spray-drying process. Pharm Dev Technol 2012;17(4):389-97.
86. Hsu SH, Reklaitis GV, Venkatasubramanian V. Modeling and control of roller compaction for pharmaceutical manufacturing. Part I: Process dynamics and control framework. J Pharm Innov 2010; 5(1-2):14-23.
87. Sun CC, Hou H, Gao P, Ma C, Medina C, Alvarez FJ. Development of a high drug load tablet formulation based on assessment of powder manufacturability: moving towards quality by design. J Pharm Sci 2009; 98(1):239-47.
88. Aksu B, Paradkar A, de Matas M, Özer Ö, Güneri T, York P. A quality by design approach using artificial intelligence techniques to control the critical quality attributes of Ramipril tablets manufactured by wet granulation. Pharm Dev Technol 2013; 18(1):236-45.
89. Meenakshi K. Chauhan, Nidhi Bhatt. Bioavailability Enhancement of Polymyxin B With Novel Drug Delivery: Development and Optimization Using Quality-by-Design Approach. J Pharm Sci 2019; 108(4):1521-1528.
90. Parmar K, Patel J, Sheth N. Formulation and development of Embelin liquisolid systems using quality by design approach. J Pharm Investig 2016; 46(6):547-56.
91. Agrawal AM, Pandey P. Scale up of pan coating process using quality by design principles. J Pharm Sci 2015; 104(11):3589-611.
92. Bülbül EO, Mesut B, Cevher E, Öztaş E, Özsoy Y. Product transfer from lab-scale to pilot-scale of quetiapine fumarate orodispersible films using quality by design approach. J Drug Deliv Sci Tec 2019. Doi: https://doi.org/10.1016/j.jddst.2019.101358
93. Kualiti MP. Spectrophotometric quantification of Vilazodone hydrochloride in pharmaceutical dosage form using quality by design approach. Malaysian Journal of Analytical Sciences 2015; 19(5):920-9.
94. Moreira CS, Lourenço FR. Development and optimization of a stability-indicating chromatographic method for Verapamil hydrochloride and its impurities in tablets using an analytical quality by design (AQbD) approach. Microchem J 2020. Doi: https://doi.org/10.1016/j.microc.2020.104610
95. Panda SS, Bera VV, Beg S, Sahu SK. Ultrafast liquid chromatographic method development and its validation for quantification of Telaprevir in pharmaceutical dosage form by using quality by design approach. J Chromatogr Sci 2015; 53(7):1193-202.
96. Schmidt AH, Molnár I. Using an innovative Quality-by-Design approach for development of a stability indicating UHPLC method for Ebastine in the API and pharmaceutical formulations. J Pharm Biomed Anal 2013; 78-79:65-74.
97. Pasquini B, Orlandini S, Furlanetto S, Gotti R, Bubba MD, Boscaro F et al. Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a Liquid chromatography-Tandem mass spectrometry method for the determination of Nintedanib and its impurities. J Chromatogr A 2020. Doi: https://doi.org/10.1016/j.chroma.2019.460615
98. Hetrick EM, Vannoy J, Montgomery LL, Pack BW. Integrating Tristimulus colorimetry into pharmaceutical development for color selection and physical appearance control: a quality-by-design approach. J Pharm Sci 2013; 102(8):2608-21.
99. Orlandini S, Pasquini B, Caprini C, Del Bubba M, Pinzauti S, Furlanetto S. Analytical Quality by Design in pharmaceutical quality assurance: Development of a capillary electrophoresis method for the analysis of Zolmitriptan and its impurities. Electrophoresis 2015; 36(21-22):2642-9.
100. Jenke D. Application of quality by design (QbD) principles to Extractables / Leachables assessment. Establishing a design space for terminally sterilized aqueous drug products stored in a plastic packaging system. PDA J Pharm Sci Technol 2010; 64(6):527-35.
101. Ende D, Bronk KS, Mustakis J, O’Connor G, Santa Maria CL, Nosal R, Watson TJ. API quality by design example from the Torcetrapib manufacturing process. Journal of Pharmaceutical Innovation 2007; 2(3-4):71-86.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).